StreetAlpha
13F holdings · Q3 2026

Caligan Partners

New York, NY · files as Caligan Partners LP
Know the moment Caligan Partners filesYou follow Caligan Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1727492

Caligan Partners reported 26 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (24.6%), LQDA (15.0%) and ABVX (9.4%). Compared with Q2 2026, the fund opened new positions in OBX, EPRX and TCGX, added to ADMA, IMCR and AVTX, trimmed IRD and ARTV and sold out of XENE and MBX.

Latest filing: what Caligan Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
3 new10 added2 trimmed2 sold outBought about $60.5M · sold about $67.1M
New 3
Added 10
See all 10 →
Trimmed 2
Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.6B−21.2% vs last quarter
Stocks held263 new · 2 sold out
Top 5 weight62.3%very concentrated
Turnover8%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$403M24.6%2MNo change7 of 8
2
LQDA
Liquidia Corporation
$246M15.0%8.1MNo change8 of 8
3
ABVX
Abivax SA
$154M9.4%1.6MNo change8 of 8
4
PCVX
Vaxcyte Inc
$125M7.6%2.2MNo change4 of 8
5
EXEL
Exelixis Inc
$90.7M5.5%1.6MNo change8 of 8
6
TNGX
Tango Therapeutics Inc
$62.4M3.8%2.5MNo change4 of 8
7
ADMA
Adma Biologics Inc
$58.9M3.6%5.9M+150K (+3%)5 of 8
8
IMCR
Immunocore Hldgs PLC
$50.6M3.1%1.7M+291K (+21%)2 of 8
9
AVTX
Avalo Therapeutics Inc
$50.1M3.1%3.3M+104K (+3%)5 of 8
10
LBRX
LB Pharmaceuticals Inc
$49.6M3.0%1.5M+72K (+5%)3 of 8
🔒 16 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
XENE
Xenon Pharmaceuticals Inc
$53.7M890K
MBX
Mbx Biosciences Inc
$11M200K

Reported value

last 8 quarters
$395MQ4 '24
$479MQ1 '25
$515MQ2 '25
$721MQ3 '25
$1.1BQ4 '25
$1.4BQ1 '26
$2.1BQ2 '26
$1.6BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Caligan Partners 13F FAQ

What does Caligan Partners own?

Caligan Partners reported 26 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (24.6%), LQDA (15.0%) and ABVX (9.4%). The table above lists every position in the filing (the top 10 without an account).

What did Caligan Partners buy and sell in Q3 2026?

Compared with Q2 2026: 3 new positions, 10 added to, 2 trimmed and 2 sold out. New positions include OBX, EPRX and TCGX. It sold all of XENE and MBX.

When will Caligan Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Caligan Partners's portfolio worth?

The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.